IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
Product Class Date Terms of Agreement
Xyotax (drug delivery
system, poliglumex
paclitaxel)
indacaterol +
mometasone (QMF 149)
Albuferon (albinterferon
alfa-2b)
L 2006 Licensed-in from Cell Therapeutics. Novartis agreed to
take an 8% stake in the firm and also has an option to
license pixantrone.
R 2006 Collaboration with Schering-Plough to develop a fixed
combination of the corticosteroid mometasone and
indacaterol, as a once-daily inhaled treatment for asthma
and COPD.
J 2006 Human Genome Sciences granted Novartis rights to
co-market in the USA and rights to market the product in
territories outside the USA. Clinical development costs
will be shared. HGS will receive an upfront payment of
$45 million as well as clinical development, commercial
milestone and other payments of up to $507.5 million.
Y 39983 S 2005 Licensed rights to Y 39983 from Senju.
AT 9311/AT 7519 L 2005 Licensed global rights to AT 9311 from Astex, plus an
option to license AT 7519.
SBR 759 V 2005 Licensed in worldwide rights from SeBo.
NM 100060 J 2005 Exclusive global licensing deal with NexMed for NexMed’s
proprietary NM 100060 terbinafine nail lacquer treatment
for onychomycosis.
RSV 604 J 2005 Novartis agreed to develop, commercialize and fund all
future work related to Arrow’s RSV 604. Rights to
back-up compounds to RSV 604 are included in the deal
plus a right of first negotiation on follow-up compounds
with different chemistry, in development with Arrow (now
part of AstraZeneca).
drug delivery system,
inhaled glycopyrronium
bromide
R 2005 Licensed-in from Ventura and Arakis (now Sosei).
© 2009 IMS Health In cor po rated or its af fil i ates Page 128